Aditxt (ADTX) CEO Amro Albanna Resigns; Jeffrey Busch Named Interim CEO, Shares Plunge

Aditxt (ADTX) chief executive Amro Albanna resigned on Monday, June 1, 2026, and the biotech company appointed board member Jeffrey Busch as interim CEO, triggering a sharp decline in the stock in after-hours trading. The company did not provide a reason for the abrupt departure. Busch will assume day-to-day leadership while the board searches for a permanent replacement. Albanna had led Aditxt through its early development of immune-modulating therapies. The leadership shakeup comes at a critical time as the company works to advance its pipeline and secure financing. Shares fell heavily, reflecting investor concern over the unexpected change.